目的 探讨不同分子分型乳腺浸润性导管癌手术病例标本中P53、表皮生长因子受体（EGFR）和Ki-67的表达及临床意义。 方法 采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连接法法对2010年1月－2011年7月446例乳腺浸润性导管癌患者标本进行分子分型，并同时检测其P53、EGFR、Ki-67等的表达。 结果 P53和Ki-67在人类表皮生长因子受体2（HER2）过表达型、基底细胞样型、未分类型中的表达明显强于管腔A型及管腔B型（P＜0.05）；HER2过表达型和未分类型中的EGFR表达明显强于管腔A型及管腔B型（P＜0.05）。 结论 在使用雌激素受体、c-erbB-2等指标对浸润性导管癌进行分子分型时同时检测P53、EGFR及Ki-67等标记物，有助于更加精准的评估肿瘤的生物学行为及预后 ，对靶向药物的个体化治疗提供参考和疗效预测有重要意义。
Objective To explore the values of different clinical parameters and biochemistry indicators to monitor and predict diabetic retinopathy (DR). Methods The study involved 250 patients with type 2 diabetes mellitus (DM). The patients were divided into DR group (100 patients) with expected sensitivity (Sen) 80％, without DR group (150 patients) with expected specificity (Spe) 60％. DR related clinical and biochemical indicators which including peripheral blood plasma endothelin-1 (ET-1), peripheral vascular endothelial growth factor, plasma magnesium, renal function related indicators, islet function related indicators, blood rheology and blood lipids were detected. Receiver operating characteristic (ROC) was used to analyze accuracy; count the area under a curve (AUC), Sen, Spe and Youden index; develop joint diagnostic testing program. Results The parameters or indicators with clinical value of DR early warning included age, DM duration, plasma ET-1, serum magnesium and urinary albumin (P＜0.05). In the period of mild non-progressive DR, plasma ET-1 had the highest diagnostic validity (AUC=0.742,Spe=72.00%, Sen=72.20%); in moderate and severe non-progressive DR period, urinary albumin had the highest diagnosis validity (AUC=0.742, Spe=56.10%, Sen=87.88%); in the progressive DR period, the diagnostic validity of plasma ET-1 was highest (AUC=0.857, Spe=84.00%, Sen=85.71%). The joint program with the highest Youden index was DM duration combined with plasma ET-1 serial test, and the early warning value was that DM duration exceeded 3.5 years and the tested plasma ET-1 was greater than 160.00 pg/ml. Conclusions Age, DM duration, plasma ET-1, serum magnesium and urinary albumin are the significant parameters or indicators for DR early warning. Joint diagnostic tests can help patients to monitor the progression of DR.